Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.

计划入组 1,550 人

MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers

计划入组 55 人 · 首次发布于 2022 年 3 月 9 日

A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis

计划入组 32 人 · 首次发布于 2026 年 8 月 17 日

ERAPOL (Poliovirus infection), Biological E Ltd

inactivated polio vaccine

MRBEV

BIOLOGICAL E. LIMITED

India

Biological E Limited.

United States

HUALAN BIOLOGICAL ENGINEERING. INC.

Biological E Receives WHO Phase II Pre-Qualification for Novel Oral Polio Vaccine Type 2

GSK and Biological E Form Joint Venture to Develop Novel Six-in-One Pediatric Vaccine

ICMR Licenses Three Indigenous Biomedical Technologies to Emcure and Biological E for Cancer and Infectious Disease Control